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5-lipoxygenase (5-LO) pathway is the major source of potent proinﬂammatory leukotrienes (LTs) issued from the metabolism of
arachidonic acid (AA), and best known for their roles in the pathogenesis of asthma. These lipid mediators are mainly released from
myeloid cells and may act as physiological autocrine and paracrine signalling molecules, and play a central role in regulating the
interaction between innate and adaptive immunity. The biological actions of LTs including their immunoregulatory and proinﬂam-
matory eﬀects are mediated through extracellular speciﬁc G-protein-coupled receptors. Despite their role in inﬂammatory cells, such
as neutrophils and macrophages, LTs may have important eﬀects on dendritic cells (DC)-mediated adaptive immunity. Several lines
of evidence show that DC not only are important source of LTs, but also become targets of their actions by producing other lipid
mediators and proinﬂammatory molecules. This review focuses on advances in 5-LO pathway biology, the production of LTs from
DC and their role on various cells of immune system and in adaptive immunity.
INTRODUCTION
Leukotrienes (LTs) are an important family of eicos-
anoid lipid mediators derived from the metabolism of
arachidonic acid (AA) and associated with asthma and al-
lergic reactions [1]. In contrast to prostaglandins (PGs),
which are produced from AA by the action of cyclooxyge-
nase (COX) enzymes, LTs are made predominately by in-
ﬂammatory cells like polymorphonuclear leukocytes [2],
activated macrophages [3], and mast cells [4]. Dendritic
cells (DC) are the major players in both innate and adap-
tive immunity [5]. Despite their important role as the
most professional antigen-presenting cells (APC) of the
immune system, DC possess the enzymatic machinery to
c o n v e r tA At op r o i n ﬂ a m m a t o r yL T s[ 6, 7, 8, 9]. Since,
all human DC phenotypes examined until now consti-
tutively express the 5-LO pathway, the role of DC 5-LO-
derived lipid mediators in the regulation of the proxi-
mal steps of the immune responses was recently suggested
[8].Primaryimmuneresponseinvolvesphenomenaasdi-
verseasantigenuptakebyDC,theirsubsequentmigration
through multiple tissue barriers, homing in lymphoid or-
gans, and antigen presentation to T cells [8, 9]. LTs could
play roles in each of these events. It is known that LTs ex-
ert their eﬀects through extracellular G-protein-coupled
receptors. Among human tissues studied by Northern
blot analysis, LTB4 receptor messenger RNA (mRNA) is
strongly expressed in both thymus [10]a n dl y m p hn o d e s
(Spanbroek R. unpublished data), while CysLT1 recep-
tor mRNA is expressed in spleen [11]. In addition, 5-LO-
deﬁcientmiceshowalteredovalbumin-dependentcellular
and humoral immune responses [12, 13]. These observa-
tions provided substantial support for an indispensable
role of 5-LO pathway in the regulation of adaptive immu-
nity. Since LTs display a great variety of biological eﬀects,
it is not surprising that cellular LT biosynthesis must be
tightly regulated. Based in the current knowledge of 5-LO
pathway regulation, it becomes obvious that cellular LT
biosynthesis is modulated by multiple mechanisms, in-
cluding gene expression, cytokine eﬀects, enzyme move-
ment, and compartmentalization of the 5-LO pathway.
Thus the understanding of the precise regulatory mech-
anism of the 5-LO activity might provide new concepts
for the development of anti-inﬂammatory drugs.
5-LO PATHWAY AND LT BIOSYNTHESIS
LTs are lipid messengers that play central role in im-
mune responses and tissue homeostasis [14]. Biosynthe-
sis of LTs from AA was initially described in polymor-
phonuclear leukocytes and monocytes. First described
in 1937 as the slow reacting substances of anaphylaxis
(SRS-A), these lipid mediators are now known as the
cysteinyl LTs (CysLTs), LTC4,L T D 4 and LTE4 [15]. Syn-
thesis of LTs can be divided in two pathways: one to
create CysLTs and another to create LTB4 (Figure 1).
Some of important properties of 5-LO pathway pro-
teins are summarized in Table 1. 5-LO is the key en-
zyme in LT biosynthesis and is located in the nucleus in
some cell types and in the cytosol of others [16]. 5-LO
is 72- to 80-kd monomeric soluble protein containing
one nonheme iron believed necessary for catalysis [17].100 H. Hedi and G. Norbert 2004:2 (2004)
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Figure 1. Pathways of LT biosynthesis. Arachidonic acid is lib-
erated from membrane phospholipids by the action of cytoso-
lic phospholipase A2 (cPLA2) and presented to 5-LO enzyme
by FLAP. 5-LO enzyme converts arachidonic acid to an un-
stable intermediate termed 5-hydroperoxyeicosatetraenoic acid
(5-HPETE). Subsequently, 5-HPETE is dehydrated to yield the
epoxide LTA4, a pivotal intermediate in the biosynthesis of in-
ﬂammatory and anaphylactic mediators. Enzymatic hydrolysis
of LTA4 by LTA4 hydrolase results in the formation of LTB4.A l -
ternatively,LTC4 synthasecatalyzestheconjunctionofLTA4 with
glutathione to form LTC4,w h i c hm a yb ec o n v e r t e dt oL T D 4 and
LTE4 by the actions of the transferase and peptidase enzymes,
respectively.
This enzyme possesses an NH2-terminal domain that
binds to calcium iron and is essential for nuclear mem-
brane translocation [18]. Active mainly in myeloid cells,
such as monocytes, macrophages, B lymphocytes, gran-
ulocytes, mast cells, and DC, 5-LO requires Ca2+ and
is stimulated by ATP, phosphatidylcholine, lipids, and
hydroperoxides [19]. Following cellular activation, 5-LO
translocates to the nuclear membrane where it is able to
interact with an 18-kd membrane-associated protein re-
ferred to as ﬁve-lipoxygenase-activating protein (FLAP).
FLAP is an AA-binding protein whose function is to op-
timally present substrate to 5-LO [20]. The ﬁrst evidence
that the 18-kd protein is absolutely required for cellular
5-LO activity comes from transfection studies in human
osteosarcoma cell lines [21]. In this system, expression of
5-LO alone resulted in no detectable cellular 5-LO activ-
ity following challenge with calcium ionophore A-23187.
LTsynthesis onlyoccurredwhen5-LOandFLAPwereco-
expressed in these cells. FLAP is expressed on T cells [22],
macrophages, and DC [6], but not on erythrocytes or en-
dothelial cells.
Cellular activation by immune complexes, bacterial
peptides, and other stimuli elicit a sequence of events
that include cytosolic phospholipase A2 (cPLA2)a n d5 -
LO translocation to the nuclear envelope to produce 5-
hydroperoxy eicosatetraenoic acid (5-HPETE) from AA.
Subsequently, 5-HPETE is dehydrated to yield the epox-
ide LTA4, a pivotal intermediate in the biosynthesis of
inﬂammatory and anaphylactic mediators. LTA4 under-
goes transformation by one or more of three possible
fates depending on the cellular context: hydrolysis, con-
jugation with glutathione, or transcellular metabolism to
generate bioactive lipid mediators [23]. In neutrophils
and monocytes, LTA4 is converted predominately to the
chemoattractant LTB4 by LTA4 hydrolase [24], but in hu-
man eosinophils, mast cells, and basophils, LTA4 is conju-
gated with reduced glutathione by LTC4 synthase to form
the ﬁrst of the CysLTs, LTC4 [25]. After carrier-mediated
cellular export, sequential cleavage of the glutathionyl
side chain of LTC4 generates the extracellular metabolites
LTD4 and LTE4.L T B 4 m a yb ed e g r a d e db ym i c r o s o m a lω-
oxidation and peroxisomal β-oxidation in myeloid cells
and hepatocytes. Degradation is accompanied by loss of
biological activity. It is important to note that degradative
enzymes are increased by the transcription factor perox-
isome proliferator-activated receptor α (PPARα) and this
nuclear hormone receptor is in turn activated by binding
with LTB4 [26]. This feedback loop limits the duration of
action of LTB4.
RECEPTORS FOR LEUKOTRIENES
TheactionsofLTsrequiretheexpressionofextracellu-
lar G-protein-coupled receptors (GPCR) which are mem-
bers of the rhodopsin-like receptor superfamily. LTB4 is a
potent chemoattractant that is primarily involved in in-
ﬂammation, immune responses, and host defense against
infection. LTB4 activates inﬂammatory cells by binding to
its cell-surface receptor (designated BLT) via two known
receptors, BLT1 and BLT2, according to the aﬃnity of
LTB4 for the receptor. BLT1 has been characterized as a
43-kdGPCRexpressedonlyininﬂammatorycells,includ-
ing neutrophils, alveolar macrophages, and eosinophils
and with a high aﬃnity for only LTB4 [27]. The second
G-protein-coupled receptor for LTB4, BLT2 receptor, has
only recently been described and is a low-aﬃnity recep-
tor expressed more ubiquitously [28, 29]. Both recep-
tors are found in lymph node [30] on the same chro-
mosome, but intriguingly, the promoter region of the
BLT1 gene is localized within the open reading frame
(ORF) of the BLT2 gene, which encodes a low-aﬃnity2004:2 (2004) On the Role of Leukotrienes in Dendritic Cell Functions 101
Table 1. 5-lipoxygenase pathway proteins.
5-lipoxygenase FLAP LTA4 hydrolase LTC4 synthase
78kd, cytosolic protein 18kd, membrane protein 69kd, cytosolic protein 18kd, membrane protein
673 amino acid AA-binding protein Converts LTA4 to LTB4 Converts LTA4 to LTC4
Nonheme iron Required for activation of 5-LO
Translocated to cell membrane
after cell activation
Dioxygenase activity converts AA
to 5-HPETE
Dehydratase activity converts
5-HPETE to LTA4
receptor for LTB4 [27]. The high-aﬃnity receptor BLT1
mediates chemotaxis, chemokinesis, aggregation, and ad-
herence to endothelium. The low-aﬃnity receptor BLT2
mediates degranulation and oxygen radical release [31].
Overexpression of LTB4 receptors in leukocytes leads to
increased neutrophil inﬂux into the lungs after ischemia-
reperfusion in mice [32]. It is also important to indi-
cate that LTB4 can bind and activate the intranuclear
transcription factor PPARα, resulting in the activation of
genesthatterminateinﬂammatoryprocesses[10].There-
ceptor for cysteinyl LTs, LTC4,L T D 4,a n dL T E 4 are named
CysLT receptors and are distinct from the LTB4 recep-
tors. Two classes of CysLT receptors have been identiﬁed:
CysLT1 and CysLT2 according to their sensitivity to selec-
tive LT receptor antagonists. CysLT1 has been identiﬁed
in human smooth muscle cells [11], vascular endothelial
cells [33], lung macrophages, and peripheral blood leuko-
cytes. CysLT2 receptor, originally found in pulmonary
vein preparations [34] by pharmacological assays, is de-
tected in spleen, Purkinje ﬁbers of the heart, and discreet
region of the adrenal gland by molecular methods.
REGULATORY MECHANISMS OF CELLULAR
LT BIOSYNTHESIS
Abnormal production of LT contributes to a vari-
ety of inﬂammatory diseases, including asthma, glomeru-
lonephritis, psoriasis, inﬂammatory bowel diseases, and
acute lung injury [35]. Considering their important role
in host defense against microbial infections [36], biosyn-
thesis of LTs must be tightly regulated. Two steps seem to
be involved in the control of LT biosynthesis, that is, liber-
ation of AA and regulation of 5-LO activity [37]. More-
over, the expression of 5-LO and FLAP, which are sub-
j e c tt or e g u l a t i o ni nm o n o c y t i cc e l l s[ 38], have been con-
sidered as the major determinant of cellular LT biosyn-
thesis [39]. 5-LO activity and product generation at sites
of inﬂammation might be modulated in multiple ways.
The most obvious would be the recruitment and stimula-
tion of additional inﬂammatory cells. Another possibility
is modulating the expression of enzymatic components
through transcriptional or posttranscriptional mecha-
nisms. Recently, it has been reported that cyclic AMP
(cAMP) elevating agents, such as PGE2, inhibited LT
biosynthesis and 5-LO translocation to the nucleus in
cytokine-primed human neutrophils [40]. The intracel-
lular compartmentalization of the 5-LO metabolism af-
fects the integrated output of this biosynthetic pathway
[41]. Nuclear import of 5-LO can modulate LT produc-
tion, since nuclear import can strongly enhance [42]o r
suppress[43]5-LOactivity.Inconsideringthequestionof
5-LO translocation and its cellular localization, it is nec-
essary to consider that 5-LO can move in or out of the nu-
cleusinresponsetoinvivoorinvitroexperimentalcondi-
tions [41]. Cytokines and other components may also af-
fect 5-LO pathway, and the expression of 5-LO and FLAP
can be controlled by speciﬁc molecules. For example, it
has been reported that the Th2-derived cytokines, IL-4,
and IL-13 inhibited the release of LT from monocytes
by decreasing FLAP mRNA and protein levels, whereas,
IL-1 and IFNγ (Th1 cytokines) stimulate 5-LO expres-
sion [39]. 5-LO activity may be modulated by nitric ox-
ide (NO) since prolonged exposure to lipopolysaccharide
inhibits macrophage 5-LO metabolism via induction of
NO synthesis [44]. In bone marrow-derived DC, we have
recently demonstrated that exogenous or PGE2-induced
IL-10 inhibited FLAP expression without any eﬀect on 5-
LO enzyme [6]. The regulatory mechanisms of the 5-LO
pathway appear to be complex and depends on the com-
position of the investigated cell populations. Speciﬁc con-
trol of 5-LO pathway has long been suspected because ex-
pression of 5-LO activity is tissue speciﬁc and narrowly
distributed to inﬂammatory cells. It is also important to
note that there is wide variation in 5-LO activity and in 5-
L Oa n dF L A Pl e v e l se v e na m o n gd i ﬀerent inﬂammatory
cell types.
5-LO PATHWAY AND CELLS OF IMMUNE SYSTEM:
WHAT ABOUT DENDRITIC CELLS?
One of the best known and most well-studied LTs is
LTB4.L T B 4 is produced by many cells of the immune102 H. Hedi and G. Norbert 2004:2 (2004)
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Figure 2. Eﬀects of LTB4 on cells of immune system.
system, including activated neutrophils stimulated with
AA or calcium ionophore [45], macrophages, DC, and T
cells [46, 47]. This lipid mediators has diverse eﬀects on
the function and activities of cells of the immune system
(Figure 2). Several observations have suggested that LTB4,
in cooperation with monocytes, stimulates T-suppressor-
cell functions [48, 49]. These eﬀects appeared to be ex-
ertedthroughinhibitionofTCD4+ (helper/inducer)sub-
sets and enhancement of T CD8+ (suppressor/cytotoxic)
subsets [50]. The suppression required the presence of
monocytes and was induced by the cyclooxygenase in-
hibitors [51]. It has been suggested that the mechanism of
action involved induction of monocytes to produce both
prostaglandins (metabolites of cyclooxygenase pathways)
and cytokines, such as IFN-γ,I L - 2 ,w h i c hi nt u r nl e a dt o
the production of IL-1 [52, 53]. Thus, the eﬀects of LTB4
on T lymphocytes are not the result of a direct action on
lymphocytes themselves but an indirect action via mono-
cytes. On natural killer (NK) cells, LTB4 signiﬁcantly aug-
mented NK cell cytotoxicity and stimulated the expres-
sion of IL-2 β receptors when added to eﬀector target co-
cultures [54, 55]. LTB4 is also known to enhance B cell
diﬀerentiation and secretion of IgE via an IL-4-dependent
mechanism [56]. LTB4 causes adhesion and chemotactic
movement of leukocytes and stimulates aggregation, en-
zymerelease,andgenerationofsuperoxideinneutrophils.
Leukotrienes C4,D 4,a n dE 4, which are released from the
lung tissue of asthmatic subjects exposed to speciﬁc al-
lergens, seem to play a pathophysiological role in imme-
diate hypersensitivity reactions. The expression of 5-LO
and FLAP genes have been reported in human B cells
by reversed transcription chain analysis [22]. Several AA-
derived lipid mediators possess immunoregulatory prop-
erties in vivo and in vitro. The most interesting example
is PGE2,w h i c hc l e a r l ya ﬀects the functions of DC and
other cell types of the immune system [57]. In contrast
to PGE2,L T B 4 is considered as a mainly immunopotenti-
ating mediator, which stimulates the activity of NK cells
and B lymphocytes, although it also induces suppressor
function among human mononuclear leukocytes. LTB4
can augment proliferation of mixed T lymphocytes and of
OKT8+ cells [58]. It also stimulates the release of IL-1 and
TNF-α in human monocytes [59], and IL-8 from human
polymorphonuclear leukocytes [60].2004:2 (2004) On the Role of Leukotrienes in Dendritic Cell Functions 103
Cells that produce LTs or become targets to their ac-
tions can also produce other proinﬂammatory molecules,
such as PGs, and various cytokines. For example, the ex-
ogenously added or the endogenously produced LTB4 can
enhance the release of IL-6 from human monocytes [61]
and mice DC [6]. This may constitute an important mean
by which monocytes and DC modulate inﬂammatory re-
sponses. Several lines of evidence support an expanded
role of the 5-LO pathway in the regulation of antigen-
speciﬁc adaptive immunity. Epidermal Langerhans cells
(LC), a member of the DC family capable of initiating
antigen-speciﬁc immune responses in naive lymphocytes,
markedly express the 5-LO pathway [9]. We have recently
demonstrated that mice bone marrow-derived DC (BM-
DC) produce LTB4 and other AA metabolites, which have
an autocrine actions in APC-mediated immunity [6, 7].
Other investigators have reported the expression of 5-
LO in human DC generated from CD34+ hematopoietic
progenitors and in lymphoid organs [8]. It has been re-
cently reported that BM-DC express CysLT1 receptors, 5-
LO, FLAP, and LTC4 synthase, and produce CysLTs in re-
sponse to aeroallergen [62]. The produced CysLTs play a
crucial role in regulating DC function in a murine model
for asthma. The ability of DC to migrate to lymphoid
nodes may be aﬀected by 5-LO products since the LTC4
transporter MRP1 may regulate CCL19-dependent mo-
bilization of DC from peripheral tissues to lymph nodes
[63]. Taken together, these data suggest that by produc-
ing proinﬂammatory LTs and other components, DC and
other APC may play important role in inﬂammatory pro-
cesses and allergic diseases.
CONCLUDING REMARKS
The main function of the immune system is the de-
fence of the host against pathogens and tumors. Two ma-
jor defence systems are involved in host defence against
infectious agents and tumors: the innate and adaptive im-
munity,whichdiﬀerinthemeansbywhichtheyrecognize
antigens. However, it is important to indicate that innate
immune system activates, orientates, and regulates the
adaptive immunity, which through clonal expansion of
lymphocytes will respond to pathogen in antigen speciﬁc
manner. Both innate and adaptive immunity are closely
linked, and the interactions between the two systems of
the host defence are regulated by a variety of cells and
their mediators in particular cytokines and AA-derived
lipid mediators, such as LTs.
The development of speciﬁc agonists and antagonists
f o re a c hL Tr e c e p t o r sw i l lp r o v i d ei m p o r t a n tr e a g e n tf o r
further deﬁning the biological and pathological actions
ofproinﬂammatoryLTs.Otherlipoxygenaseproductswill
also certainly receive attention in the year to come. To de-
lineate molecular mechanisms within immune responses
that are aﬀected by 5-LO pathway products, future stud-
ies should be directed toward DC/T lymphocytes inter-
actions, the identiﬁcation of LT receptor-expressing cells
in lymphoid organs, and immune response studies of 5-
LO knockout mice. Finally, further studies of LT recep-
torsexpressionindiﬀerenttypesofDCandotherAPCare
needed to truly assess the potential roles of 5-LO pathway
in DC biology and APC-mediated immunity.
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